Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Daniel G. Coit; John A. Thompson; Robert Andtbacka; Christopher J. Anker; Christopher K. Bichakjian; William E. Carson; Gregory A. Daniels; Adil Daud; Dominick DiMaio; Martin D. Fleming; Rene Gonzalez; Valerie Guild; Allan C. Halpern; F. Stephen Hodi; Mark C. Kelley; Nikhil I. Khushalani; Ragini R. Kudchadkar; Julie R. Lange; Mary C. Martini; Anthony J. Olszanski; Merrick I. Ross; April Salama; Susan M. Swetter; Kenneth K. Tanabe; Vijay Trisal; Marshall M. Urist; Nicole R. McMillian; Maria Ho

doi:10.6004/jnccn.2014.0066

Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. OlszanskiMerrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, Maria Ho

Research output: Contribution to journal › Review article › peer-review

57 Scopus citations

Abstract

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

Original language	English
Pages (from-to)	621-629
Number of pages	9
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	12
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2014.0066
State	Published - 2014

Access to Document

10.6004/jnccn.2014.0066

Cite this

Coit, D. G., Thompson, J. A., Andtbacka, R., Anker, C. J., Bichakjian, C. K., Carson, W. E., Daniels, G. A., Daud, A., DiMaio, D., Fleming, M. D., Gonzalez, R., Guild, V., Halpern, A. C., Hodi, F. S., Kelley, M. C., Khushalani, N. I., Kudchadkar, R. R., Lange, J. R., Martini, M. C., ... Ho, M. (2014). Melanoma, version 4.2014: Featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 12(5), 621-629. https://doi.org/10.6004/jnccn.2014.0066

@article{983830fdedda45c49d9d5b870de42865,

title = "Melanoma, version 4.2014: Featured updates to the NCCN guidelines",

abstract = "The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.",

author = "Coit, {Daniel G.} and Thompson, {John A.} and Robert Andtbacka and Anker, {Christopher J.} and Bichakjian, {Christopher K.} and Carson, {William E.} and Daniels, {Gregory A.} and Adil Daud and Dominick DiMaio and Fleming, {Martin D.} and Rene Gonzalez and Valerie Guild and Halpern, {Allan C.} and Hodi, {F. Stephen} and Kelley, {Mark C.} and Khushalani, {Nikhil I.} and Kudchadkar, {Ragini R.} and Lange, {Julie R.} and Martini, {Mary C.} and Olszanski, {Anthony J.} and Ross, {Merrick I.} and April Salama and Swetter, {Susan M.} and Tanabe, {Kenneth K.} and Vijay Trisal and Urist, {Marshall M.} and McMillian, {Nicole R.} and Maria Ho",

year = "2014",

doi = "10.6004/jnccn.2014.0066",

language = "English",

volume = "12",

pages = "621--629",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "5",

}

Coit, DG, Thompson, JA, Andtbacka, R, Anker, CJ, Bichakjian, CK, Carson, WE, Daniels, GA, Daud, A, DiMaio, D, Fleming, MD, Gonzalez, R, Guild, V, Halpern, AC, Hodi, FS, Kelley, MC, Khushalani, NI, Kudchadkar, RR, Lange, JR, Martini, MC, Olszanski, AJ, Ross, MI, Salama, A, Swetter, SM, Tanabe, KK, Trisal, V, Urist, MM, McMillian, NR & Ho, M 2014, 'Melanoma, version 4.2014: Featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 12, no. 5, pp. 621-629. https://doi.org/10.6004/jnccn.2014.0066

TY - JOUR

T1 - Melanoma, version 4.2014

T2 - Featured updates to the NCCN guidelines

AU - Coit, Daniel G.

AU - Thompson, John A.

AU - Andtbacka, Robert

AU - Anker, Christopher J.

AU - Bichakjian, Christopher K.

AU - Carson, William E.

AU - Daniels, Gregory A.

AU - Daud, Adil

AU - DiMaio, Dominick

AU - Fleming, Martin D.

AU - Gonzalez, Rene

AU - Guild, Valerie

AU - Halpern, Allan C.

AU - Hodi, F. Stephen

AU - Kelley, Mark C.

AU - Khushalani, Nikhil I.

AU - Kudchadkar, Ragini R.

AU - Lange, Julie R.

AU - Martini, Mary C.

AU - Olszanski, Anthony J.

AU - Ross, Merrick I.

AU - Salama, April

AU - Swetter, Susan M.

AU - Tanabe, Kenneth K.

AU - Trisal, Vijay

AU - Urist, Marshall M.

AU - McMillian, Nicole R.

AU - Ho, Maria

PY - 2014

Y1 - 2014

N2 - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

AB - The NCCN Guidelines for Melanoma provide multidisciplinary recommendations for the management of patients with melanoma. These NCCN Guidelines Insights highlight notable recent updates. Dabrafenib and trametinib, either as monotherapy (category 1) or combination therapy, have been added as systemic options for patients with unresectable metastatic melanoma harboring BRAF V600 mutations. Controversy continues regarding the value of adjuvant radiation for patients at high risk of nodal relapse. This is reflected in the category 2B designation to consider adjuvant radiation following lymphadenectomy for stage III melanoma with clinically positive nodes or recurrent disease.

UR - http://www.scopus.com/inward/record.url?scp=84900423555&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000335718600004&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2014.0066

DO - 10.6004/jnccn.2014.0066

M3 - Review article

C2 - 24812131

SN - 1540-1405

VL - 12

SP - 621

EP - 629

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 5

ER -

Melanoma, version 4.2014: Featured updates to the NCCN guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this